Thursday, 11 June 2026 | 15:25 - 15:45
argenx's Immunology Innovation Program - Heleen Dewitte, argenx
Through innovation and fruitful partnership with academia, argenx has built a broad clinical development pipeline of differentiated antibody candidates that show promise in treating a variety of severe autoimmune and neurological disorders. Antibodies can be designed with modifications to their variable and/or constant regions, giving them clinically beneficial properties, such as an extended half-life, enhanced cell killing, clearance of antigens from the bloodstream (“sweeping”), or modulation/ablation of downstream Fc-effector functions.
1 speaker
Principle Scientist Discovery
argenx